Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 63 entries
Sorted by: Best Match Show Resources per page
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Experimental hematology & oncology

Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S.
PMID: 29152412
Exp Hematol Oncol. 2017 Nov 09;6:30. doi: 10.1186/s40164-017-0090-5. eCollection 2017.

BACKGROUND: Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET) and polycythemia vera (PV). We recently reported results of a phase...

Cite
Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6:30doi: 10.1186/s40164-017-0090-5.
Masarova, L., Yin, C. C., Cortes, J. E., Konopleva, M., Borthakur, G., Newberry, K. J., Kantarjian, H. M., Bueso-Ramos, C. E., & Verstovsek, S. (2017). Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Experimental hematology & oncology, 630. https://doi.org/10.1186/s40164-017-0090-5
Masarova, Lucia, et al. "Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)." Experimental hematology & oncology vol. 6 (2017): 30. doi: https://doi.org/10.1186/s40164-017-0090-5
Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017 Nov 09;6:30. doi: 10.1186/s40164-017-0090-5. eCollection 2017. PMID: 29152412; PMCID: PMC5679503.
Copy Download .nbib Format: NLM
Correlation of tissue biopsy and fine needle aspiration cytology with positron emission tomography results.

Pathology research international

Rosen D, Herrington B, Bhargava P, Laucirica R, Verstovsek G.
PMID: 21559200
Patholog Res Int. 2011 Apr 06;2011:323051. doi: 10.4061/2011/323051.

F-18-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) scans are positive in any condition which increases metabolism in a mass or tissue and are therefore not specific for neoplastic conditions. The use of an SUV cutoff value of 2.5 may not...

Cite
Rosen D, Herrington B, Bhargava P, et al. Correlation of tissue biopsy and fine needle aspiration cytology with positron emission tomography results. Patholog Res Int. 2011;2011:323051doi: 10.4061/2011/323051.
Rosen, D., Herrington, B., Bhargava, P., Laucirica, R., & Verstovsek, G. (2011). Correlation of tissue biopsy and fine needle aspiration cytology with positron emission tomography results. Pathology research international, 2011323051. https://doi.org/10.4061/2011/323051
Rosen, Daniel, et al. "Correlation of tissue biopsy and fine needle aspiration cytology with positron emission tomography results." Pathology research international vol. 2011 (2011): 323051. doi: https://doi.org/10.4061/2011/323051
Rosen D, Herrington B, Bhargava P, Laucirica R, Verstovsek G. Correlation of tissue biopsy and fine needle aspiration cytology with positron emission tomography results. Patholog Res Int. 2011 Apr 06;2011:323051. doi: 10.4061/2011/323051. PMID: 21559200; PMCID: PMC3090089.
Copy Download .nbib Format: NLM
Ruxolitinib for essential thrombocythemia?.

Oncoscience

Bose P, Verstovsek S.
PMID: 29344542
Oncoscience. 2017 Nov 01;4(11):148-149. doi: 10.18632/oncoscience.373. eCollection 2017 Nov.

No abstract available.

Cite
Bose P, Verstovsek S. Ruxolitinib for essential thrombocythemia?. Oncoscience. 2017;4(11):148-149doi: 10.18632/oncoscience.373.
Bose, P., & Verstovsek, S. (2017). Ruxolitinib for essential thrombocythemia?. Oncoscience, 4(11), 148-149. https://doi.org/10.18632/oncoscience.373
Bose, Prithviraj, and Verstovsek, Srdan. "Ruxolitinib for essential thrombocythemia?." Oncoscience vol. 4,11 (2017): 148-149. doi: https://doi.org/10.18632/oncoscience.373
Bose P, Verstovsek S. Ruxolitinib for essential thrombocythemia?. Oncoscience. 2017 Nov 01;4(11):148-149. doi: 10.18632/oncoscience.373. eCollection 2017 Nov. PMID: 29344542; PMCID: PMC5769968.
Copy Download .nbib Format: NLM
Therapy-related myelofibrosis does not appear to exist.

Blood advances

Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S.
PMID: 29296729
Blood Adv. 2017 May 26;1(14):863-866. doi: 10.1182/bloodadvances.2017007369. eCollection 2017 Jun 13.

There is no evidence to support the existence of therapy-related myelofibrosis.Therapy for previous malignancy has no impact on myelofibrosis prognosis.

Cite
Masarova L, Todisco G, Manshouri T, et al. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017;1(14):863-866doi: 10.1182/bloodadvances.2017007369.
Masarova, L., Todisco, G., Manshouri, T., Newberry, K. J., Cortes, J. E., Kantarjian, H. M., Estrov, Z., & Verstovsek, S. (2017). Therapy-related myelofibrosis does not appear to exist. Blood advances, 1(14), 863-866. https://doi.org/10.1182/bloodadvances.2017007369
Masarova, Lucia, et al. "Therapy-related myelofibrosis does not appear to exist." Blood advances vol. 1,14 (2017): 863-866. doi: https://doi.org/10.1182/bloodadvances.2017007369
Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 May 26;1(14):863-866. doi: 10.1182/bloodadvances.2017007369. eCollection 2017 Jun 13. PMID: 29296729; PMCID: PMC5737601.
Copy Download .nbib Format: NLM
Paradigm shift: combination BET and JAK inhibition in myelofibrosis.

Leukemia

Mascarenhas J, Gerds A, Verstovsek S.
PMID: 34480105
Leukemia. 2021 Dec;35(12):3361-3363. doi: 10.1038/s41375-021-01405-z. Epub 2021 Sep 03.

No abstract available.

Cite
Mascarenhas J, Gerds A, Verstovsek S. Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia. 2021;35(12):3361-3363doi: 10.1038/s41375-021-01405-z.
Mascarenhas, J., Gerds, A., & Verstovsek, S. (2021). Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia, 35(12), 3361-3363. https://doi.org/10.1038/s41375-021-01405-z
Mascarenhas, John, et al. "Paradigm shift: combination BET and JAK inhibition in myelofibrosis." Leukemia vol. 35,12 (2021): 3361-3363. doi: https://doi.org/10.1038/s41375-021-01405-z
Mascarenhas J, Gerds A, Verstovsek S. Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia. 2021 Dec;35(12):3361-3363. doi: 10.1038/s41375-021-01405-z. Epub 2021 Sep 03. PMID: 34480105.
Copy Download .nbib Format: NLM
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells.

Oncotarget

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z.
PMID: 33747356
Oncotarget. 2021 Mar 02;12(5):401-411. doi: 10.18632/oncotarget.27884. eCollection 2021 Mar 02.

The glioma associated oncogene-1 (GLI1), a downstream effector of the embryonic Hedgehog pathway, was detected in chronic lymphocytic leukemia (CLL), but not normal adult cells. GLI1 activating mutations were identified in 10% of patients with CLL. However, what induces...

Cite
Rozovski U, Harris DM, Li P, et al. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021;12(5):401-411doi: 10.18632/oncotarget.27884.
Rozovski, U., Harris, D. M., Li, P., Liu, Z., Jain, P., Manshouri, T., Veletic, I., Ferrajoli, A., Bose, P., Thompson, P., Jain, N., Verstovsek, S., Wierda, W., Keating, M. J., & Estrov, Z. (2021). STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget, 12(5), 401-411. https://doi.org/10.18632/oncotarget.27884
Rozovski, Uri, et al. "STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells." Oncotarget vol. 12,5 (2021): 401-411. doi: https://doi.org/10.18632/oncotarget.27884
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02;12(5):401-411. doi: 10.18632/oncotarget.27884. eCollection 2021 Mar 02. PMID: 33747356; PMCID: PMC7939524.
Copy Download .nbib Format: NLM
SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

Clinical lymphoma, myeloma & leukemia

Bose P, Verstovsek S.
PMID: 34272171
Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):641-649. doi: 10.1016/j.clml.2021.06.008. Epub 2021 Jun 23.

Over the last decade, the Janus kinase (JAK) 1/2 inhibitor ruxolitinib has become widely established as the cornerstone of pharmacologic therapy for most patients with myelofibrosis (MF), providing dramatic and durable benefits in terms of splenomegaly and symptoms, and...

Cite
Bose P, Verstovsek S. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021;21(10):641-649doi: 10.1016/j.clml.2021.06.008.
Bose, P., & Verstovsek, S. (2021). SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clinical lymphoma, myeloma & leukemia, 21(10), 641-649. https://doi.org/10.1016/j.clml.2021.06.008
Bose, Prithviraj, and Verstovsek, Srdan. "SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis." Clinical lymphoma, myeloma & leukemia vol. 21,10 (2021): 641-649. doi: https://doi.org/10.1016/j.clml.2021.06.008
Bose P, Verstovsek S. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):641-649. doi: 10.1016/j.clml.2021.06.008. Epub 2021 Jun 23. PMID: 34272171; PMCID: PMC8565615.
Copy Download .nbib Format: NLM
An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma.

Clinical case reports

Khan S, Premji S, Huang Q, Verstovsek G, Bushan S, Yellapragada SV.
PMID: 34938552
Clin Case Rep. 2021 Dec 09;9(12):e05176. doi: 10.1002/ccr3.5176. eCollection 2021 Dec.

We present a case of a 58-year-old male patient who presented to his primary care clinic with complaints of eye swelling and fatigue. Workup ultimately led to a diagnosis of AL amyloidosis secondary to myeloma based on SLiM-CRAB criteria....

Cite
Khan S, Premji S, Huang Q, et al. An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma. Clin Case Rep. 2021;9(12):e05176doi: 10.1002/ccr3.5176.
Khan, S., Premji, S., Huang, Q., Verstovsek, G., Bushan, S., & Yellapragada, S. V. (2021). An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma. Clinical case reports, 9(12), e05176. https://doi.org/10.1002/ccr3.5176
Khan, Shamis, et al. "An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma." Clinical case reports vol. 9,12 (2021): e05176. doi: https://doi.org/10.1002/ccr3.5176
Khan S, Premji S, Huang Q, Verstovsek G, Bushan S, Yellapragada SV. An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma. Clin Case Rep. 2021 Dec 09;9(12):e05176. doi: 10.1002/ccr3.5176. eCollection 2021 Dec. PMID: 34938552; PMCID: PMC8659555.
Copy Download .nbib Format: NLM
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.

HemaSphere

Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X, Harrison CN.
PMID: 33969273
Hemasphere. 2021 Apr 29;5(5):e553. doi: 10.1097/HS9.0000000000000553. eCollection 2021 May.

Patients with myelofibrosis (MF) experience an array of symptoms that impair health-related quality of life (HRQoL). Fedratinib, an oral, selective Janus-kinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, phase III JAKARTA study in adult patients with intermediate-...

Cite
Mesa RA, Schaap N, Vannucchi AM, et al. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. Hemasphere. 2021;5(5):e553doi: 10.1097/HS9.0000000000000553.
Mesa, R. A., Schaap, N., Vannucchi, A. M., Kiladjian, J. J., Passamonti, F., Zweegman, S., Talpaz, M., Verstovsek, S., Rose, S., Abraham, P., Lord-Bessen, J., Tang, D., Guo, S., Ye, X., & Harrison, C. N. (2021). Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HemaSphere, 5(5), e553. https://doi.org/10.1097/HS9.0000000000000553
Mesa, Ruben A, et al. "Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial." HemaSphere vol. 5,5 (2021): e553. doi: https://doi.org/10.1097/HS9.0000000000000553
Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X, Harrison CN. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. Hemasphere. 2021 Apr 29;5(5):e553. doi: 10.1097/HS9.0000000000000553. eCollection 2021 May. PMID: 33969273; PMCID: PMC8096463.
Copy Download .nbib Format: NLM
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.

Therapeutics and clinical risk management

Ostojic A, Vrhovac R, Verstovsek S.
PMID: 22399854
Ther Clin Risk Manag. 2012;8:95-103. doi: 10.2147/TCRM.S23277. Epub 2012 Mar 01.

Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is dysregulated, leading to impaired hematopoiesis and immune function. By...

Cite
Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag. 2012;8:95-103doi: 10.2147/TCRM.S23277.
Ostojic, A., Vrhovac, R., & Verstovsek, S. (2012). Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and clinical risk management, 895-103. https://doi.org/10.2147/TCRM.S23277
Ostojic, Alen, et al. "Ruxolitinib for the treatment of myelofibrosis: its clinical potential." Therapeutics and clinical risk management vol. 8 (2012): 95-103. doi: https://doi.org/10.2147/TCRM.S23277
Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag. 2012;8:95-103. doi: 10.2147/TCRM.S23277. Epub 2012 Mar 01. PMID: 22399854; PMCID: PMC3295626.
Copy Download .nbib Format: NLM
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Blood advances

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.
PMID: 29296774
Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.

Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1)...

Cite
Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017;1(17):1312-1323doi: 10.1182/bloodadvances.2017008227.
Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., Borthakur, G., Konopleva, M., Bhalla, K. N., Daver, N., DiNardo, C. D., Benton, C. B., Takahashi, K., Estrov, Z., Pierce, S. R., Andreeff, M., Cortes, J. E., & Kadia, T. M. (2017). Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood advances, 1(17), 1312-1323. https://doi.org/10.1182/bloodadvances.2017008227
Boddu, Prajwal, et al. "Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis." Blood advances vol. 1,17 (2017): 1312-1323. doi: https://doi.org/10.1182/bloodadvances.2017008227
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25. PMID: 29296774; PMCID: PMC5727976.
Copy Download .nbib Format: NLM
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.

HemaSphere

Bose P, Verstovsek S.
PMID: 32903304
Hemasphere. 2020 Jul 21;4(4):e424. doi: 10.1097/HS9.0000000000000424. eCollection 2020 Aug.

The 2011 approval of ruxolitinib ushered in the Janus kinase (JAK) inhibitor era in the treatment of myelofibrosis (MF), and 2019 saw the US approval of fedratinib. The first therapeutic agents approved by regulatory authorities for MF, these drugs...

Cite
Bose P, Verstovsek S. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. Hemasphere. 2020;4(4):e424doi: 10.1097/HS9.0000000000000424.
Bose, P., & Verstovsek, S. (2020). JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. HemaSphere, 4(4), e424. https://doi.org/10.1097/HS9.0000000000000424
Bose, Prithviraj, and Verstovsek, Srdan. "JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives." HemaSphere vol. 4,4 (2020): e424. doi: https://doi.org/10.1097/HS9.0000000000000424
Bose P, Verstovsek S. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. Hemasphere. 2020 Jul 21;4(4):e424. doi: 10.1097/HS9.0000000000000424. eCollection 2020 Aug. PMID: 32903304; PMCID: PMC7375176.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 63 entries